Abstract
Atherosclerosis has been recognized as an inflammatory disease. The innate and adaptive immunity mechanisms are involved in atherogenesis. Low-grade inflammation is associated with innate immunity activation. The CRP has been proposed as the best indicator of low-grade inflammation and a predictor of cardiovascular events. A triumvirate of targets in the prevention of CVD are: LDL-C aggressive lowering, HDL-C increasing and CRP lowering. The statins role in lipids and CRP lowering is well established. Moreover, statins may be beneficial in many other inflammatory immune conditions. Among PPAR-α agonists, anti-inflammatory properties of fenofibrate are the best demonstrated. PPAR-γ agonists (thiazolidinediones) pleiotropic effects are also promising. PPAR α/γ agonists have been proved to cause severe side effects. Ezetimibe exerts beneficial anti-inflammatory actions when administered with statins. Colesevelam, a novel bileacid sequestrant has beneficial lipid-lowering and anti-inflammatory actions. CETP and ACAT inhibitors actions call for further studies. Inhibition of CRP, CRP-targeted antisenses, HDL-particle modification and immunomodulation of atherosclerosis are possible novel approaches in atherosclerosis treatment and prevention.
Keywords: Atherosclerosis, inflammation, immune system, CRP, statins, fibrates
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Lipid Lowering Agents, Inflammation and Atherosclerosis
Volume: 7 Issue: 3
Author(s): Marlena Broncel, Marzena Kozirog and Julita Chojnowska-Jezierska
Affiliation:
Keywords: Atherosclerosis, inflammation, immune system, CRP, statins, fibrates
Abstract: Atherosclerosis has been recognized as an inflammatory disease. The innate and adaptive immunity mechanisms are involved in atherogenesis. Low-grade inflammation is associated with innate immunity activation. The CRP has been proposed as the best indicator of low-grade inflammation and a predictor of cardiovascular events. A triumvirate of targets in the prevention of CVD are: LDL-C aggressive lowering, HDL-C increasing and CRP lowering. The statins role in lipids and CRP lowering is well established. Moreover, statins may be beneficial in many other inflammatory immune conditions. Among PPAR-α agonists, anti-inflammatory properties of fenofibrate are the best demonstrated. PPAR-γ agonists (thiazolidinediones) pleiotropic effects are also promising. PPAR α/γ agonists have been proved to cause severe side effects. Ezetimibe exerts beneficial anti-inflammatory actions when administered with statins. Colesevelam, a novel bileacid sequestrant has beneficial lipid-lowering and anti-inflammatory actions. CETP and ACAT inhibitors actions call for further studies. Inhibition of CRP, CRP-targeted antisenses, HDL-particle modification and immunomodulation of atherosclerosis are possible novel approaches in atherosclerosis treatment and prevention.
Export Options
About this article
Cite this article as:
Broncel Marlena, Kozirog Marzena and Chojnowska-Jezierska Julita, Lipid Lowering Agents, Inflammation and Atherosclerosis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7 (3) . https://dx.doi.org/10.2174/187152308785699254
DOI https://dx.doi.org/10.2174/187152308785699254 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Strategy on Antimicrobial-resistance: Inhibitors of DNA Replication Enzymes
Current Medicinal Chemistry Retracted: Junk Food Consumption, Perceptions and Associated Factors among the Private School Children
Current Nutrition & Food Science Anti-Inflammatory Effects of Fibrates: An Overview
Current Medicinal Chemistry The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Water in the Brain: Role of Aquaporin-4 in Ischemic Brain Edema
Current Drug Targets Update in the Management of Diastolic Heart Failure
Current Vascular Pharmacology Arterial Stiffness and Hypertension: A Review of Mechanism and Clinical Relevance
Current Hypertension Reviews Organoselenium Compounds as Potential Therapeutic and Chemopreventive Agents: A Review
Current Medicinal Chemistry New Immunosuppressants: Immunosuppression and Immunomodulation
Medicinal Chemistry Reviews - Online (Discontinued) PDE-5 Inhibitors: Clinical Points
Current Drug Targets Prevention of Postprandial Metabolic Stress in Humans: Role of Fruit- Derived Products
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological manipulation of peripheral vascular resistance in special clinical situations after pediatric cardiac surgery
Current Vascular Pharmacology Antihypertensive Therapy: Role of Aldosterone Antagonists
Current Pharmaceutical Design Platelets and Platelet Interaction with Progenitor Cells in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Discovery of Chromen-7-yl Furan-2-Carboxylate as a Potent and Selective Factor XIa Inhibitor
Cardiovascular & Hematological Agents in Medicinal Chemistry Interaction of the Heart and Lungs During Exercise: Physiology and Pathophysiology in Children with Congenital Heart Disease
Current Respiratory Medicine Reviews Advantages and Limitations of Transgenic Mice: The Role of the Na<sup>+</sup>/Ca<sup>2+</sup> Exchanger in Cardiac Electrophysiology and Arrhythmia
Current Medicinal Chemistry Chemoprevention of Lung Pathologies by Dietary n-3 Polyunsaturated Fatty Acids
Current Medicinal Chemistry HM74a Agonists: Will they be the New Generation of Nicotinic Acid?
Current Topics in Medicinal Chemistry Sex-Gender Differences in Diabetes Vascular Complications and Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets